A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: Implication for the molecular mechanism of drug resistance and sensitivity

Amino Acids

Volumn 46, Issue 7, 2014, Pages 1635-1648

  Ai, Xinghao ^a   Sun, Yingjia ^a   Wang, Haidong ^b   Lu, Shun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Drug resistance and sensitivity; Epidermal growth factor receptor; Kinase inhibitor; Non small cell lung cancer; Somatic amino acid mutation

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AFN 941; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; LAPATINIB; OSI 776; STAUROSPORINE; TAK 285; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; MOLECULAR LIBRARY; PROTEIN KINASE INHIBITOR;

ARTICLE; BINDING AFFINITY; BINDING SITE; CALCULATION; CANCER RESISTANCE; CONCENTRATION RESPONSE; DENSITY FUNCTIONAL THEORY; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; IC 50; IN VITRO STUDY; LIGAND BINDING; LUNG NON SMALL CELL CANCER; MATHEMATICAL ANALYSIS; MOLECULAR MECHANICS; PRIORITY JOURNAL; QUANTUM MECHANICS; RECEPTOR BINDING; SOMATIC MUTATION; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; MOLECULAR GENETICS; MOLECULAR LIBRARY; MUTATION; PHARMACOLOGY; STRUCTURE ACTIVITY RELATION;

BACTERIA (MICROORGANISMS); LENTZEA ALBIDA;

AMINO ACID SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; COMPUTER SIMULATION; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMALL MOLECULE LIBRARIES; STAUROSPORINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84903601129     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-014-1716-0     Document Type: Article

References (52)

1. Alzate-Morales JH, Caballero J, Vergara Jague A, González Nilo FD (2009) Insights into the structural basis of N2 and O6 substituted guanine derivatives as cyclin-dependent kinase 2 (CDK2) inhibitors: prediction of the binding modes and potency of the inhibitors by docking and ONIOM calculation. J Chem Inf Model 49:886-899
2. Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA, Pao W (2006) Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12:6494-6501 (Pubitemid 44799723)
3. Bashford D, Case DA (2000) Generalized born models of macromolecular solvation effects. Annu Rev Phys Chem 51:129-152
4. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The protein data bank. Nucleic Acids Res 28:235-242 (Pubitemid 30047768)
5. Brignola PS, Lackey K, Kadwell SH, Hoffman C, Horne E, Carter HL, Stuart JD, Blackburn K, Moyer MB, Alligood KJ, Knight WB, Wood ER (2002) Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. Demonstration of differential sensitivity to kinase inhibitors. J Biol Chem 277:1576-1585 (Pubitemid 34968916)
6. Carmi C, Galvani E, Vacondio F, Rivara S, Lodola A, Russo S, Aiello S, Bordi F, Costantino G, Cavazzoni A, Alfieri RR, Ardizzoni A, Petronini PG, Mor M (2012) Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides. J Med Chem 55:2251-2264
7. Case DA, Cheatham TE 3rd, Darden T, Gohlke H, Luo R, Merz KM Jr, Onufriev A, Simmerling C, Wang B, Woods RJ (2005) The Amber biomolecular simulation programs. J Comput Chem 26:1668-1688 (Pubitemid 43076180)
8. Chung JY, Chung HW, Cho SJ, Hah JM, Cho AE (2010) QM/MM based 3D QSAR models for potent B-Raf inhibitors. J Comput Aided Mol Des 24:385-397
9. Comell WD, Cieplak P, Bayly CI, Kollman PA (1993) Application of RESP charges to calculate conformational energies, hydrogen bond energies, and free energies of solvation. J Am Chem Soc 115:9620-9631
10. Costa DB, Schumer ST, Tenen DG, Kobayashi S (2008) Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. J Clin Oncol 26:1182-1184
11. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 29:1046-1051
12. Doebele RC, Oton AB, Peled N, Camidge DR, Bunn PA Jr (2010) New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer 69:1-12
13. Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, Zhang W, Yang R, Cieplak P, Luo R, Lee T, Caldwell J, Wang J, Kollman P (2003) Point-charge force field for molecular mechanics simulations of proteins. J Comput Chem 24:1999-2012
14. Eisenberg D, McLachlan AD (1986) Solvation energy in protein folding and binding. Nature 319:199-203 (Pubitemid 16128783)
15. Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, Lélias JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, Lockhart DJ (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23:329-336 (Pubitemid 41094421)
16. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Zakrzewski VG, Montgomery JA Jr, Stratmann RE, Burant JC, Dapprich S, Millam JM, Daniels AD, Kudin KN, Strain MC, Farkas O, Tomasi J, Barone V, Cossi M, Cammi R, Mennucci B, Pomelli C, Adamo C, Clifford S, Ochterski J, Petersson GA, Ayala PY, Cui Q, Morokuma K, Malick DK, Rabuck AD, Raghavachari K, Foresman JB, Cioslowski J, Ortiz JV, Stefanov BB, Liu G, Liashenko A, Piskorz P, Komaromi I, Gomperts R, Martin RL, Fox DJ, Keith T, Al-Laham MA, Peng CY, Nanayakkara A, Gonzalez C, Challacombe M, Gill PMW, Johnson BG, Chen W, Wong MW, Andres JL, Head-Gordon M, Replogle ES, Pople JA (2003) Gaussian 03. Gaussian Inc., Wallingford
17. Fu Z, Li X, MerzKMJr (2011) Accurate assessment of the strain energy in a protein-bound drug using QM/MM X-ray refinement and converged quantum chemistry. J Comput Chem 32:2587-2597
18. Gleeson MP, Gleeson D (2009a) QM/MM calculations in drug discovery: a useful method for studying binding phenomena? J Chem Inf Model 49:670-677
19. Gleeson MP, Gleeson D (2009b) QM/MM as a tool in fragment based drug discovery. A cross-docking, rescoring study of kinase inhibitors. J Chem Inf Model 49:1437-1448
20. Guo X, He D, Liu L, Kuang R, Liu L (2012) Use of QM/MM scheme to reproduce macromolecule-small molecule noncovalent binding energy. Comput Theor Chem 991:134-140
21. Hayik SA, Dunbrack R Jr, Merz KM Jr (2010) A mixed QM/MM scoring function to predict protein-ligand binding affinity. J Chem Theory Comput 6:3079-3091
22. Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I (2009) Mechanisms of tumor resistance to EGFRtargeted therapies. Expert Opin Ther Targets 13:339-362
23. Kollman PA, Massova I, Reyes C, Kuhn B, Huo SH, Chong L, Lee M, Duan Y, Wang W, Donini O, Cieplak P, Srinivasan J, Case DA, Cheatham TE (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 33:889-897 (Pubitemid 32056774)
24. Li Y, Yang Y, He P, Yang Q (2009) QM/MM study of epitope peptides binding to HLA-A*0201: the roles of anchor residues and water. Chem Biol Drug Des 74:611-618
25. Lin L, Bivona TG (2012) Mechanisms of resistance to epidermal growth factor receptor inhibitors and novel therapeutic strategies to overcome resistance in NSCLC patients. Chemother Res Pract 2012:817297
26. Lovell SC, Word JM, Richardson JS, Richardson DC (2000) The penultimate rotamer library. Proteins 40:389-408 (Pubitemid 30624447)
27. Lu Y, Shi T, Wang Y, Yang H, Yan X, Luo X, Jiang H, Zhu W (2009) Halogen bonding - a novel interaction for rational drug design. J Med Chem 52:2854-2862
28. Ma C, Wei S, Song Y (2011) T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis 3:10-18
29. Ohashi K, Maruvka YE, Michor F, Pao W (2013) Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 31:1070-1080
30. Peng YH, Shiao HY, Tu CH, Liu PM, Hsu JT, Amancha PK, Wu JS, Coumar MS, Chen CH, Wang SY, Lin WH, Sun HY, Chao YS, Lyu PC, Hsieh HP, Wu SY (2013) Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors. J Med Chem 56:3889-3903
31. Polyansky AA, Zubac R, Zagrovic B (2012) Estimation of conformational entropy in protein-ligand interactions: a computational perspective. Methods Mol Biol 819:327-353
32. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A (2001) The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8:11-31 (Pubitemid 32520251)
33. Riely GJ, Politi KA, Miller VA, Pao W (2006) Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 12:7232-7241 (Pubitemid 46095394)
34. Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, Isla D, Provencio M, Cobo M, Insa A, Garcia-Campelo R, Reguart N, Majem M, Viteri S, Carcereny E, Porta R, Massuti B, Queralt C, de Aguirre I, Sanchez JM, Sanchez-Ronco M, Mate JL, Ariza A, Benlloch S, Sanchez JJ, Bivona TG, Sawyers CL, Taron M (2011) Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small- cell lung cancer patients with EGFR mutations. Clin Cancer Res 17:1160-1168
35. Rüegg UT, Burgess GM (1989) Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases. Trends Pharm Sci 10:218-220 (Pubitemid 19146392)
36. Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169-181
37. Shigematsu H, Gazdar AF (2006) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118:257-262 (Pubitemid 41779062)
38. Siegel-Lakhai WS, Beijnen JH, Schellens JH (2005) Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist 10:579-589 (Pubitemid 41429121)
39. Svensson M, Humbel S, Froese RDJ, Matsubara T, Sieber S, Morokuma K (1996) ONIOM: a multilayered integrated MO + MM method for geometry optimizations and single point energy predictions. A test for Diels-Alder reactions and Pt(P(t- Bu)(3))(2) + H-2 oxidative addition. J Phys Chem 100: 19357-19363 (Pubitemid 126786970)
40. Takezawa K, Okamoto I, Tanizaki J, Kuwata K, Yamaguchi H, Fukuoka M, Nishio K, Nakagawa K (2010) Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther 9:1647-1656
41. Tan F, Shen X, Wang D, Xie G, Zhang X, Ding L, Hu Y, He W, Wang Y, Wang Y (2012) Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer 76:177-182
42. Tian F, Yang L, Lv F, Luo X, Pan Y (2011a) Why OppA protein can bind sequence-independent peptides? A combination of QM/ MM, PB/SA, and structure-based QSAR analyses. Amino Acid 40:493-503
43. Tian F, Lv Y, Zhou P, Yang L (2011b) Characterization of PDZ domain-peptide interactions using an integrated protocol of QM/ MM, PB/SA, and CFEA analyses. J Comput Aided Mol Des 25:947-958
44. Veale D, Ashcroft T, Marsh C, Gibson GJ, Harris AL (1987) Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer 55:513-516 (Pubitemid 17098858)
45. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Developing and testing of a general amber force field. J Comput Chem 25:1157-1174
46. Yoshikawa S, Kukimoto-Niino M, Parker L, Handa N, Terada T, Fujimoto T, Terazawa Y, Wakiyama M, Sato M, Sano S, Kobayashi T, Tanaka T, Chen L, Liu ZJ, Wang BC, Shirouzu M, Kawa S, Semba K, Yamamoto T, Yokoyama S (2013) Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor. Oncogene 32:27-38
47. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, Eck MJ (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11:217-227 (Pubitemid 46349842)
48. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M, Eck MJ (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105:2070-2075 (Pubitemid 351439466)
49. Zhang C, Vasmatzis G, Cornette JL, DeLisi C (1997) Determination of atomic desolvation energies from the structures of crystallized proteins. J Mol Biol 267:707-726 (Pubitemid 27170692)
50. Zhou P, Tian F, Shang Z (2009a) 2D depiction of nonbonding interactions for protein complexes. J Comput Chem 30:940-951
51. Zhou P, Zou J, Tian F, Shang Z (2009b) Fluorine bonding - how does it work in protein-ligand interactions? J Chem Inf Model 49:2344-2355
52. Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck MJ, Gray NS, Jänne PA (2009c) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462:1070-1074